Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity. Speculative; first target does not pay enough. Speculative watch only. Confirmation remains mandatory: 15-minute reversal around $14.20-$14.50.
Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity. The company is also developing BHV-1510 that is in Phase 2 clinical trial for the treatment of advanced or metastatic epithelial tumors; and BHV-1530, which is in Phase 2 clinical trial for treating urothelial cancer and other tumors. In addition, its preclinical product pipeline includes BHV-1310 for treating myasthenia gravis; BHV-1320 for treating immune mediated-diseases; BHV-1450 for treating Pemphigus, MuSK MG, and LGI-1 Encephalitis; BHV-1420 for treating membranous nephropathy; BHV-1440 for treating Graves' disease and TED; BHV-6500 for treating type 1 diabetes; BHV-1490 for treating IgM neuropathy and Waldenstrom's; BHV-8100 for treating neurodegenerative diseases; and BHV-1955 for treating tinnitus. The company was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.
| Metric | Value | Signal |
|---|---|---|
| Revenue (TTM) | $0 | 0.0% YoY |
| EBITDA | N/A | Not meaningful / unavailable |
| Gross Margin | 0.0% | Reported |
| Operating Margin | N/A | Not meaningful without revenue |
| Net Margin | N/A | Not meaningful without revenue |
| ROE | -799.5% | Capital efficiency |
| Cash | $267.9M | Liquidity |
| Debt | $297.0M | Balance-sheet claim |
| Forward P/E | N/A | No estimate substituted |
| Intrinsic-value model | N/A | Fail-closed: insufficient inputs |
| Value / quality panel | 0 positive / 5 negative / 0 neutral | bearish / confidence 66 |
| Analyst Mean Target | $21.73 | Consensus, not a guarantee |
| Quarter | EPS Actual | EPS Est. | Surprise | Revenue |
|---|---|---|---|---|
| 2Q2025 | $-1.63 | $-1.57 | -4.0% | - |
| 3Q2025 | $-1.64 | $-1.93 | 14.9% | - |
| 4Q2025 | $-0.90 | $-0.96 | 5.8% | - |
| 2Q2026 | $-0.78 | $-0.61 | -27.6% | - |
2/4 captured quarters beat estimates — Next: 2026-11-09T20:00:00Z
No structured transaction table was captured; aggregate counts are not used.
Authorized: Program disclosed in the 424B5 | Used: $178.9M net in the first half | Remaining: $350M
The ATM issued 17.16M shares for $178.9M net in the first half and still had $350M available. Liquidity was $267.9M versus $235.0M of first-half operating cash burn.
Official filings were reviewed through 2026-08-28; the table lists the decision-relevant documents rather than every routine filing. The D+ grade describes the full dossier; the trade state (speculative) is a separate timing decision.
| Date | Form | Accession | What the filing changes |
|---|---|---|---|
| 2026-08-10 | 10-Q | 0001935979-26-000066 | Quantifies burn, ATM issuance and the $250M secured debt. |
| 2026-08-26 | 8-K | 0001935979-26-000072 | Describes the conditional SK transaction; proceeds are not cash until closing. |
| 2026-05-04 | 424B5 | 0001628280-26-029924 | Documents the active ATM capacity. |
Current snapshot only; no acceleration claim without a comparable historical series.
Unusual Activity: No unusual activity confirmed
| RSI (14) | 60.6 |
| EMA 20 | $14.59 |
| EMA 50 | $14.03 |
| EMA 200 | $12.87 |
| MACD | 0.274 |
| Signal | 0.057 |
| ATR (14) | $1.16 |
| Wyckoff | Transitional |
Speculative; first target does not pay enough. Required confirmation: 15-minute reversal around $14.20-$14.50. Available moving averages are shown with their provider type.
| Indicator | Value | Signal |
|---|---|---|
| Market regime | Risk-on 0.79 | Trend support, not a timing trigger |
| VIX | 14.51 | Low current protection price |
Regime: risk-on
The broad regime supports long setups, but rates and ticker-specific confirmation override the label.
Dilution: high; beta: 3.16; insider signal: unavailable.
A precise stop does not make a setup valid. Entry location, normal volatility, event risk and reachable resistance decide whether the risk is paid.
No directional flow claim is made when detailed, aligned flow data is unavailable.
Speculative; first target does not pay enough. Monitor 15-minute reversal around $14.20-$14.50; no market order and no chase outside the zone.
Wait for confirmation and preserve the invalidation.
This analysis is provided for informational and educational purposes only. It does not constitute financial advice, investment recommendation, or solicitation to buy or sell any security.
Past performance is not indicative of future results. All investments involve risk, including the possible loss of principal. Always conduct your own research and consult a licensed financial advisor before making investment decisions.
Data comes from point-in-time market snapshots, company filings, Yahoo Finance, SEC EDGAR, and public market data. Accuracy is not guaranteed.
Social Radar
Pump & Dump Score: 3/6
Suspect